Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Expands By 171.0%

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 805,300 shares, an increase of 171.0% from the September 15th total of 297,200 shares. Approximately 5.3% of the company’s stock are sold short. Based on an average daily trading volume, of 1,790,000 shares, the days-to-cover ratio is currently 0.4 days.

A number of brokerages have recently commented on APRE. Berenberg Bank lowered shares of Aprea Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research report on Monday, August 16th. Zacks Investment Research lowered shares of Aprea Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 4th. Royal Bank of Canada cut their price objective on shares of Aprea Therapeutics from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research report on Friday, August 13th. Morgan Stanley lowered shares of Aprea Therapeutics from an “equal weight” rating to an “underweight” rating and cut their price objective for the stock from $5.00 to $3.00 in a research report on Thursday, August 12th. Finally, JPMorgan Chase & Co. downgraded shares of Aprea Therapeutics from a “neutral” rating to an “underweight” rating in a report on Friday, August 20th. Two research analysts have rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $4.15.

In other Aprea Therapeutics news, SVP Lars B. Abrahmsen sold 50,000 shares of Aprea Therapeutics stock in a transaction that occurred on Friday, October 1st. The shares were sold at an average price of $4.89, for a total value of $244,500.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Eyal C. Attar sold 15,968 shares of Aprea Therapeutics stock in a transaction that occurred on Thursday, September 16th. The shares were sold at an average price of $4.68, for a total transaction of $74,730.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 98,928 shares of company stock worth $483,041. Insiders own 18.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its holdings in shares of Aprea Therapeutics by 76.5% in the first quarter. Royal Bank of Canada now owns 15,173 shares of the company’s stock valued at $76,000 after purchasing an additional 6,576 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Aprea Therapeutics by 380.3% in the first quarter. JPMorgan Chase & Co. now owns 16,550 shares of the company’s stock valued at $85,000 after purchasing an additional 13,104 shares during the last quarter. Great Lakes Advisors LLC acquired a new position in shares of Aprea Therapeutics in the second quarter valued at $87,000. Ergoteles LLC acquired a new position in shares of Aprea Therapeutics in the second quarter valued at $91,000. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Aprea Therapeutics in the first quarter valued at $116,000. Hedge funds and other institutional investors own 30.73% of the company’s stock.

Shares of APRE opened at $5.58 on Thursday. The company has a market cap of $118.22 million, a price-to-earnings ratio of -2.48 and a beta of -0.12. Aprea Therapeutics has a 1-year low of $3.17 and a 1-year high of $30.99. The company’s fifty day simple moving average is $4.54 and its 200 day simple moving average is $4.64.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Thursday, August 12th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). On average, analysts predict that Aprea Therapeutics will post -1.77 earnings per share for the current year.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers.

Featured Article: What are high-yield dividend stocks?

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.